ClinicalTrials.gg
BiologicalDrug

Bizaxofusp clinical trials

studies test it
5
open now
0
in phase 3
0
first study started
1999

How each study uses bizaxofusp is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

interleukin-4 PE38KDEL cytotoxin
3

Development codes

MDNA55
1
NBI-3001
1
PRX321
1

Studies by the year they started

5 studies that test it; most in 1999 (1)

Studies that test bizaxofusp, by start year
YearStudies
19991
20011
20021
20091
20171

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 4 · Other 1

Neurocrine Biosciences (2) · Medicenna Therapeutics, Inc. (1) · Barrett Cancer Center (1) · Sophiris Bio Corp (1)

Studies

Open first, then newest update. How each study uses bizaxofusp is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Codes

What other systems call bizaxofusp · ClinicalTrials.gg INT004588

  • UNII (FDA) FRY3MOL2QUBIZAXOFUSPOne source FDA
  • NCI Thesaurus C79843BizaxofuspOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.